Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) AI Stock Analysis

• Market Cap: S$39.41M
• Dividend Yield: N/A
• Average Volume (3M): 247.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: -5.63%
• EPS Growth: 28.29%
• Country: SG
• Employees: 107
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.03
• Shares Outstanding: 1,231,494,600
• 10 Day Avg. Volume: 138,640
• 30 Day Avg. Volume: 247,960
• PEG Ratio: 0.04
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 1.94
• P/FCF Ratio: -2.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: S$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by the company's strong revenue growth, despite significant challenges in profitability and cash flow generation. Positive technical indicators provide some support, but the negative valuation metrics due to ongoing losses weigh heavily on the score.

Singapore Institute of Advanced Medicine Holdings Ltd. Business Overview & Revenue Model

Company Description

Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) is a healthcare company focused on advancing medical technologies and services. The company operates primarily in the healthcare sector, offering a range of services including medical diagnostics, advanced treatment options, and healthcare management solutions. Its core products include innovative medical devices and health-related software solutions designed to enhance patient care and streamline healthcare delivery.

How the Company Makes Money

The company generates revenue through multiple streams, primarily from the sale of medical devices and diagnostic tools, which are marketed to hospitals, clinics, and healthcare professionals. Additionally, it earns income from healthcare management services that help institutions improve operational efficiency. Strategic partnerships with medical technology firms and healthcare providers also play a crucial role in expanding its market reach and enhancing product offerings, contributing significantly to its overall earnings.

Singapore Institute of Advanced Medicine Holdings Ltd. Financial Statement Overview

Summary

The company exhibits strong revenue growth but struggles with profitability and cash flow generation. High leverage and negative returns on equity pose financial risks, while operational inefficiencies impact margins. The financial health of the company requires improvement in cost management and cash flow generation to achieve sustainable growth.

Income Statement

The company shows a significant revenue growth rate of 95.43% in the latest year, indicating strong top-line expansion. However, profitability remains a concern with negative net profit margins and EBIT margins, suggesting operational inefficiencies and high costs relative to revenue. The consistent negative margins over the years highlight ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.05, indicating significant leverage, which could pose financial risk. The return on equity is negative, reflecting losses and inefficiencies in generating returns for shareholders. However, the equity ratio is relatively stable, suggesting some level of financial stability despite the high leverage.

Cash Flow

Cash flow analysis shows negative operating cash flow, indicating challenges in generating cash from core operations. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is somewhat aligned with net income, albeit both are negative. The high free cash flow growth rate of 91.31% is a positive sign, but sustainability remains a concern given the negative cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.71M	15.71M	16.65M	16.23M	13.81M	12.92M
Gross Profit	-8.52M	14.42M	15.36M	-2.60M	-4.31M	-2.32M
EBITDA	-11.04M	-11.08M	-13.42M	-10.78M	-8.02M	-3.06M
Net Income	-26.16M	-26.16M	-37.45M	-18.07M	-12.43M	-9.35M
Balance Sheet
Total Assets	124.71M	124.71M	138.76M	159.52M	174.36M	172.08M
Cash, Cash Equivalents and Short-Term Investments	2.84M	2.84M	3.16M	11.05M	15.84M	10.29M
Total Debt	58.21M	58.21M	46.10M	80.77M	87.30M	92.26M
Total Liabilities	69.07M	69.07M	57.01M	114.60M	120.31M	112.90M
Stockholders Equity	55.64M	55.64M	81.74M	44.93M	54.05M	59.18M
Cash Flow
Free Cash Flow	-11.08M	-10.78M	-14.80M	-19.89M	-11.26M	-9.72M
Operating Cash Flow	-10.93M	-10.63M	-14.26M	-5.45M	-7.15M	-4.26M
Investing Cash Flow	112.97K	113.13K	-263.72K	-1.45M	3.72M	-5.25M
Financing Cash Flow	10.50M	10.20M	6.64M	2.11M	9.18M	10.66M

Singapore Institute of Advanced Medicine Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:9G2, the sentiment is Positive. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.88 is Neutral, neither overbought nor oversold. The STOCH value of 62.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:9G2.

Singapore Institute of Advanced Medicine Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSL	67 Neutral	$1.88B	29.01	6.20%	2.50%	8.90%	4.57%
9G2	54 Neutral	S$39.41M	-1.25	-39.37%	―	-5.63%	28.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Singapore Institute of Advanced Medicine Holdings Ltd. Corporate Events

Singapore Institute of Advanced Medicine Holds Annual General Meeting

The Singapore Institute of Advanced Medicine Holdings Ltd. held its Annual General Meeting on October 28, 2025, where key board members were introduced, and standard AGM procedures were followed. The meeting included a poll voting process for resolutions, with no questions raised by shareholders, indicating a smooth and uneventful meeting.

Singapore Institute of Advanced Medicine Secures SGX-ST Approval for New Share Listing

Singapore Institute of Advanced Medicine Holdings Ltd. has received approval from the SGX-ST for the listing and quotation of 169,474,000 new shares. This includes a debt conversion of 149,726,000 shares from Caterine Limited and a placement of 19,748,000 shares at S$0.035 each. The listing is subject to compliance with SGX-ST’s requirements, and the shares must be placed within seven market days. The SGX-ST has noted potential implications for substantial acquisitions or reverse takeovers if the company acquires assets from related parties.

Singapore Institute of Advanced Medicine Streamlines Decision-Making Process

The Singapore Institute of Advanced Medicine Holdings Ltd. has dissolved its Strategic Review Committee (SRC) as of August 8, 2025. The Board of Directors will now directly handle the functions and recommendations previously managed by the SRC to streamline decision-making and expedite the implementation of initiatives.